Sidewinder Therapeutics Raises $137 Million Series B Financing

Whitehawk Therapeutics Divests Aadi Subsidiary to Kaken Pharmaceuticals

March 26, 2025

Pharmaceuticals

Whitehawk Therapeutics completed the divestiture of Aadi Subsidiary, Inc. (including the Aadi Bioscience name, trademarks, and the FYARRO (sirolimus protein-bound particles for injectable suspension) business) to Kaken Pharmaceuticals for $100 million in cash plus customary adjustments. Whitehawk plans to use proceeds (along with a $100M PIPE financing) to develop its ADC portfolio and for general corporate and working capital needs.

Windjammer Capital Acquires Bio X Cell

December 13, 2023

Biotechnology

Windjammer Capital Investors completed a control acquisition of Bio X Cell, a producer of monoclonal antibodies for pre-clinical research, in a transaction that closed November 6, 2023. Windjammer said it will partner with management to accelerate organic growth and pursue a thesis-driven acquisition strategy to expand Bio X Cell's addressable market.

Lonza Group AG Acquires Synaffix B.V.

June 1, 2023

Biotechnology

Lonza Group AG has acquired Synaffix B.V., a Netherlands-based biotech company that commercialises a clinical-stage antibody-drug conjugate (ADC) technology platform. The deal brings Synaffix's ADC bioconjugation technology into Lonza's integrated ADC development and manufacturing offering to accelerate discovery, development, scale-up and commercialization of ADCs.

AbbVie Acquires Syndesi Therapeutics

March 1, 2022

Biotechnology

AbbVie has acquired Syndesi Therapeutics for up to US$1.0 billion, including US$130 million upfront, to strengthen its neuroscience portfolio and accelerate Syndesi's lead SV2A program SDI-118 into later-stage development. Syndesi was a Novo Seeds / UCB spin-out backed by Novo Holdings and a syndicate of Belgian and international investors.

Cyrus Biotechnology Acquires Orthogonal Biologics and Raises $18M Series B

December 6, 2021

Biotechnology

Cyrus Biotechnology completed an acquisition of Orthogonal Biologics and closed an $18 million Series B financing to build an integrated software-and-screening pre-clinical biologics discovery firm. The financing was led by a syndicate including OrbiMed Advisors, Trinity Ventures, Agent Capital and other investors, with Selecta Bioscience joining as a strategic investor; the acquisition brings Orthogonal’s deep mutational scanning protein engineering capabilities into Cyrus’s computational discovery platform.

WindRose Health Investors Recapitalizes Lykan Bioscience Holdings

June 4, 2019

Biotechnology

WindRose Health Investors completed an equity recapitalization of Lykan Bioscience Holdings, LLC, a Hopkinton, Massachusetts-based contract manufacturing services organization focused on cell and gene therapy production and logistics. The investment provides capital to support growth and the build-out of a 60,000+ square foot cGMP facility to expand manufacturing capacity; terms were not disclosed.